A lively vaccine pipeline has helped to smooth and speed the transition between US Food and Drug Administration approval and the Centers for Disease Control and Prevention’s subsequent recommendations for use, with recent approvals of three vaccine applications neatly meeting the CDC’s expectations for the 26-28 June session of its Advisory Committee on Immunization Practices.
Key Takeaways
-
FDA approvals of Merck’s Capvaxive, Moderna’s mResvia and a new claim for GSK’s Arexvy came in time for votes at CDC vaccine committee’s 26-28 June meeting.
-
CDC’s often-disputed recommendations for shared clinical decision-making for adult RSV vaccines will be revisited with the mResvia and Arexvy approvals
The FDA approvals came in the well-trod fields of pneumococcal and respiratory syncytial virus vaccines, where CDC recommendations are already complex